Global prevention and control of type 2 diabetes will require paradigm shifts in policies within and among countries

Health Affairs

Volumn 31, Issue 1, 2012, Pages 84-92

  Narayan, K M Venkat ^a   Echouffo Tcheugui, Justin B ^a   Mohan, Vishwanathan ^a   Ali, Mohammed K ^b  

^a EMORY UNIVERSITY   (United States)

^b MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; ENVIRONMENTAL FACTOR; GLUCOSE BLOOD LEVEL; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY; PREGNANCY DIABETES MELLITUS; RETINOPATHY; SECONDARY PREVENTION; STROKE; ECONOMICS; INTEGRATED HEALTH CARE SYSTEM; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT;

DELIVERY OF HEALTH CARE, INTEGRATED; DIABETES MELLITUS, TYPE 2; HEALTH POLICY; HUMANS; INTERNATIONALITY;

EID: 84855675624     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.1040     Document Type: Article

References (57)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta (GA): CDC; 2011.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-21.
3. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
4. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
5. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293-301.
6. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Costeffectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872-94.
7. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB Sr., Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13): 1728-35.
8. Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol. 2004;160(6):531-9.
9. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006; 144(7):465-74.
10. Dall T, Mann SE, Zhang Y, Martin J, Chen Y. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
11. Research!America. Facts about diabetes [Internet]. New York (NY): Lasker/Funding First; [cited 2011 Dec 13]. Available from: http:// www.laskerfoundation.org/media/pdf/factsheet3diabetes.pdf
12. Thorpe KE, Ogden LL, Galactionova K. Chronic conditions account for rise in Medicare spending from 1987 to 2006. Health Aff (Millwood). 2010;29(4):718-24.
13. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010; 55(13):1310-7.
14. Milman S, Crandall JP. Mechanisms of vascular complications in prediabetes. Med Clin North Am. 2011; 95(2):309-25, vii.
15. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(7):382-93.
16. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The longterm effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-9.
17. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28(4):888-94.
18. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetesrelated microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54(2):300-7.
19. Echouffo-Tcheugui JB, Ali MK, Griffin SJ, Narayan KM. Screening for type 2 diabetes and dysglycemia. Epidemiol Rev. 2011;33(1):63-87.
20. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17): 1566-75.
21. Temple R. Preconception care for women with diabetes: is it effective and who should provide it? Best Pract Res Clin Obstet Gynaecol. 2011;25(1):3-14.
22. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32(2):287-94.
23. Geiss LS, James C, Gregg EW, Albright A, Williamson DF, Cowie CC. Diabetes risk reduction behaviors among U.S. adults with prediabetes. Am J Prev Med. 2010; 38(4):403-9.
24. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-101.
25. Screening for type 2 diabetes. Diabetes Care. 2004;27(Suppl 1):S11-4.
26. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 148(11):846-54.
27. Standards of medical care in diabetes- 2011. Diabetes Care. 2011; 34(Suppl 1):S11-61.
28. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia. 2008;51(7):1127-34.
29. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITIONEurope): a cluster-randomised trial. Lancet. 2011;378(9786):156-67.
30. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;335(7618):486.
31. Paddison CA, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, et al. Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2009;339:b4535.
32. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and metaanalysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3): 305-12.
33. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336(7654):1180-5.
34. Chatterjee R, Narayan KM, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care. 2010;33(7):1484-90.
35. Pringle M, Stewart-Evans C, Coupland C, Williams I, Allison S, Sterland J. Influences on control in diabetes mellitus: patient, doctor, practice, or delivery of care? BMJ. 1993;306(6878):630-4.
36. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med. 2004;141(4):272-81.
37. To access the Appendix, click on the Appendix link in the box to the right of the article online
38. Health systems, patients factors, and quality of care for diabetes: a synthesis of findings from the TRIAD study. Diabetes Care. 2010;33(4): 940-7.
39. Williamson DF, Narayan KM. Identification of persons with dysglycemia: terminology and practical significance. Prim Care Diabetes. 2009;3(4):211-7.
40. Aldana S, Barlow M, Smith R, Yanowitz F, Adams T, Loveday L, et al. A worksite diabetes prevention program: two-year impact on employee health. AAOHN J. 2006; 54(9):389-95.
41. Narayan KM, Williamson DF. Prevention of type 2 diabetes: risk status, clinic, and community. J Gen Intern Med. 2010;25(2):154-7.
42. Narayan KM, Chan J, Mohan V. Early identification of type 2 diabetes: policy should be aligned with health systems strengthening. Diabetes Care. 2011;34(1):244-6.
43. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med. 2008;35(4):357-63.
44. An insurer's new approach to diabetes. New York Times. 2010 Apr 14. B1.
45. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care. 2006;29(6): 1237-41.
46. Williamson DF, Marrero DG. Scaling up type 2 diabetes prevention programs for high risk persons: progress and challenges in the United States. In: Schwarz P, Reddy P, Greaves C, Dunbar J, Schwarz J, editors. Diabetes prevention in practice. Dresden: TUMAINI Institute for Prevention Management; 2010. p.69-82.
47. Tuomilehto J, Schwarz P, Lindstrom J. Long-term benefits from lifestyle interventions for type 2 diabetes prevention: time to expand the efforts. Diabetes Care. 2011;34(Suppl 2):S210-4.
48. Mohan V, Deepa R, Deepa M, Somannavar S, Datta M. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. J Assoc Physicians India. 2005;53:759-63.
49. Centers for Disease Control and Prevention. Natural Experiments for Translation in Diabetes (NEXT-D) study [Internet]. Atlanta (GA): CDC; 2011 [cited 2011 Dec 13]. Available from: http://www.cdc.gov/diabetes/ projects/next-d.htm
50. Grants.gov. Natural experiments and effectiveness studies to identify the best policy and system level practices to prevent diabetes and its complications (U58) [Internet]. Washington (DC): Department of Health and Human Services; 2010 [cited 2011 Dec 13]. Available from: http://www.grants.gov/search/ search.do?mode=VIEW& oppId=51980
51. Teutsch SM, Fielding JE. Applying comparative effectiveness research to public and population health initiatives. Health Aff (Millwood). 2011;30(2):349-55.
52. Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases- where worlds meet. N Engl J Med. 2010;363(13):1196-8.
53. Spear S, Bowen HK. Decoding the DNA of the Toyota production system. Harv Bus Rev. 1999(Sep-Oct): 3-12.
54. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
55. Frenk J. Bridging the divide: global lessons from evidence-based health policy in Mexico. Lancet. 2006; 368(9539):954-61.
56. Prahalad CK. Aravind Eye Care-the most precious gift. In: Fortune at the bottom of the pyramid: eradicating poverty through profits. Upper Saddle River (NJ): Wharton School Publishing; 2006. p. 265-86.
57. Dabhadkar KC, Kulshreshtha A, Ali MK, Narayan KM. Prospects for a cardiovascular disease prevention polypill. Annu Rev Public Health. 2011;32:23-38.